Antisense oligonucleotide-mediated exon-skipping therapies: precision medicine spreading from Duchenne muscular dystrophy

M Matsuo - JMA journal, 2021 - jstage.jst.go.jp
In 1995, we were the first to propose antisense oligonucleotide (ASO)-mediated exon-
skipping therapy for the treatment of Duchenne muscular dystrophy (DMD), a noncurable …
被引用次数：42 相关文章
[HTML] nih.gov

[HTML][HTML] Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy

M Matsuo - JMA Journal, 2021 - ncbi.nlm.nih.gov
In 1995, we were the first to propose antisense oligonucleotide (ASO)-mediated exon-
skipping therapy for the treatment of Duchenne muscular dystrophy (DMD), a noncurable …

Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy

M Masafumi - JMA Journal, 2021 - cir.nii.ac.jp
抄録< p> In 1995, we were the first to propose antisense oligonucleotide (ASO)-mediated
exon-skipping therapy for the treatment of Duchenne muscular dystrophy (DMD), a …

Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy.

M Matsuo - JMA Journal, 2021 - europepmc.org
In 1995, we were the first to propose antisense oligonucleotide (ASO)-mediated exon-
skipping therapy for the treatment of Duchenne muscular dystrophy (DMD), a noncurable …

Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy

M Matsuo - JMA journal, 2021 - pubmed.ncbi.nlm.nih.gov
In 1995, we were the first to propose antisense oligonucleotide (ASO)-mediated exon-
skipping therapy for the treatment of Duchenne muscular dystrophy (DMD), a noncurable …